Banka BioLoo Q3 FY26 Results: Net Loss Widens to ₹12.45 Lakhs
Banka BioLoo Limited reported its unaudited financial results for the quarter ended December 31, 2025. The company incurred a net loss of ₹22.01 Lakhs on a standalone basis and ₹12.45 Lakhs on a consolidated basis. Total income for the quarter was ₹1597.28 Lakhs (standalone) and ₹1531.54 Lakhs (consolidated).
The results show a widening loss compared to the previous periods, which could impact investor sentiment and the company's stock performance.
The company reported a net loss for the quarter and nine months ended December 31, 2025, indicating a negative financial performance.
Banka BioLoo Limited (BANKA) announced the outcome of its Board Meeting held on 12 February 2026. The Board approved the unaudited financial results for the quarter and nine months ended 31 December 2025, along with the Limited Review Reports for both standalone and consolidated financials.
For the quarter ended 31 December 2025, the company reported a total income of ₹1597.28 Lakhs (standalone) and ₹1531.54 Lakhs (consolidated). Expenses for the same period were ₹1622.10 Lakhs (standalone) and ₹1548.46 Lakhs (consolidated).
The company registered a loss after tax of ₹22.01 Lakhs (standalone) and ₹12.45 Lakhs (consolidated) for the quarter. For the nine-month period ended 31 December 2025, the loss after tax stood at ₹118.85 Lakhs (standalone) and ₹121.09 Lakhs (consolidated).
Basic Earnings Per Share (EPS) for the quarter were ₹(0.20) on a standalone basis and ₹(0.14) on a consolidated basis. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, commencing at 04:00 PM and concluding at 05:30 PM on 12 February 2026.
What to do with a filing like this
Banka BioLoo Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Banka BioLoo Limited. Read the original for the full detail.